CatenaBio
Amount undisclosed
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
CatenaBio is currently valued at N/A as of April 10, 2025. The company has raised a total of $9.1M in funding.
Investment Perspective
CatenaBio's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is CatenaBio Worth in 2025?
As of 2025, CatenaBio is valued at N/A, based on the company's Later Stage VC funding round in April 10, 2025. This valuation positions CatenaBio as one of the leading private companies in the sector.
CatenaBio Valuation History
CatenaBio's funding history demonstrates steady growth and investor confidence.
How CatenaBio Valuation is Determined
Private company valuations like CatenaBio's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
CatenaBio Valuation FAQs
Is CatenaBio profitable?
CatenaBio has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does CatenaBio's valuation compare to competitors?
CatenaBio is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will CatenaBio IPO?
CatenaBio has not announced plans for an initial public offering. Until an IPO, investors can access CatenaBio shares through secondary market platforms.